S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

• Anna Sureda,
• Lorenzo Falchi,
• Sirpa Leppa,
• Joost Vermaat,
• Harald Holte,
• Martin Hutchings,
• Pieternella Lugtenburg,
• Sven de Vos,
• Pau Abrisqueta,
• Marcel Nijland,
• Reid W. Merryman,
• Jacob Haaber Christensen,
• Bjorn Wahlin,
• Kim Linton,
• Liwei Wang,
• Aqeel Abbas,
• Ali Rana,
• Syed Quadri,
• David Belada

Affiliations

Anna Sureda

1 Institut Català d’Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain

Lorenzo Falchi

2 Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, United States

Sirpa Leppa

3 University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Joost Vermaat

4 Leiden University Medical Center, Leiden, The Netherlands

Harald Holte

5 Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway

Martin Hutchings

6 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Pieternella Lugtenburg

7 On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, The Netherlands

Sven de Vos

8 Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, United States

Pau Abrisqueta

9 Hospital Universitario Vall d’Hebron, Barcelona, Spain

Marcel Nijland

10 University Medical Center Groningen and University of Groningen, Groningen, The Netherlands

Reid W. Merryman

11 Dana-Farber Cancer Institute, Boston, United States

Jacob Haaber Christensen

12 Odense University Hospital, Odense, Denmark

Bjorn Wahlin

13 Karolinska Institutet, Stockholm, Sweden

Kim Linton

14 The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom

Liwei Wang

15 Genmab, Princeton, United States

Aqeel Abbas

15 Genmab, Princeton, United States

Ali Rana

15 Genmab, Princeton, United States

Syed Quadri

16 AbbVie, North Chicago, United States

David Belada

17 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic